menu
    • menu
    [{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for CAS-1071-93-8

    Menu

    CAS-1071-93-8

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Vitargus Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

                            Details : ABV-1701 is a hyaluronic acid derived hydrogel therapy which is currently being investigated for the treatment of retinal detachment and vitreous hemorrhage.

                            Product Name : Vitargus

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 22, 2023

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in...

                            Details : ABV-1701 is a hyaluronic acid derived hydrogel therapy which is currently being investigated for the treatment of retinal detachment and vitreous hemorrhage.

                            Product Name : Vitargus

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 06, 2023

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

                            Details : Vitargus (hyaluronic acid-derived therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.

                            Product Name : Vitargus

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 17, 2022

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia

                            Details : ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH) and is used for the treatment of uncomplicated retinal detachment.

                            Product Name : Vitargus

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 05, 2022

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Selects Additional Vitargus® Phase II Study Site

                            Details : Vitargus (Hyaluronic Acid Derived Therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.

                            Product Name : Vitargus

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 09, 2022

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Provides Vitargus® Update

                            Details : Vitargus/ABV-1701 (hyaluronic acid derived therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.

                            Product Name : Vitargus

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 30, 2022

                            Lead Product(s) : ABV-1701,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth